Relief Therapeutics
Relief Therapeutics is a drug development company based in Switzerland, specializing in the research and commercialization of biopharmaceutical products derived from natural or engineered peptides and proteins. Founded in 2013, the company focuses on addressing diabetic complications and respiratory diseases. Its development pipeline includes drug candidates for rare genetic and metabolic disorders, rare connective tissue disorders, and rare lung diseases. Notable candidates in their pipeline include RLF-TD011 and RLF-100. In addition to its development efforts, Relief Therapeutics also markets several legacy products, including Cambia, Setofilm, Voltadol, and Voltfast. The majority of the company’s revenue is generated from the European market.
AdVita Lifescience develop effective products and strategies to improve the therapy and diagnosis of rare lung diseases.
APR is a pharma company developing and out-licensing new drugs and new drug formulations for a variety of applications based on the company’s science driven formulation technology and expertise.
FirstString Research, Inc., a clinical stage biotech company, is leading the translation of cell-cell communication and cell-cell contact/adhesion science into a pipeline of drugs and medical applications for scar prevention, inflammation reduction, wound healing, and complex tissue regeneration. The Company has an exclusive worldwide license from the Medical University of South Carolina (MUSC) for the connexin-technology platform and intellectual properties of a portfolio of peptides capable of modulating junctional proteins that are critical for inter-cellular communication. A Phase I human clinical trial demonstrated safety and efficacy of a lead peptide generated from the technology platform. The Company is now advancing GranexinTM Gel, a topical formulation of the lead peptide, through three Phase II human clinical trials for scar reduction and treatment of chronic wounds.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.